The role and efficacy of Vemurafenib

Vemurafenib (Vemurafenib) has been approved through the BRIM trial (Phase I, Phase II, and Phase III) after studying patients with malignant melanoma with BRAF V600E-positive mutations and showing increased overall survival and progression-free survival. Ultimately, vemurafenib showed better responses in patients with stage IIIC and IV melanoma with the BRAF V600E mutation, leading to FDA approval of the drug in August 2011.

Phase I BRIM determined the optimal dose of the drug and found it to be 960 mg taken orally twice daily. The phase II BRIM trial showed an overall response rate of 53%, ranging between partial and complete response, with a median response duration of 6.7 months. The phase III BRIM trial is a multicenter randomized controlled trial comparing vemurafenib with dacarbazine, the standard treatment for metastatic melanoma. Overall survival and progression-free survival were improved with vemurafenib compared with dacarbazine. However, this was confounded in an interim analysis in which the dacarbazine group crossed over with the vemurafenib group, showing higher efficacy and response rates in the BRAF inhibitor vemurafenib group.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.